On September 01, 2026, NovoCure Ltd (NASDAQ: NVCR) disclosed a cybersecurity breach involving unauthorized access to patient and employee data through a subsidiary in mid-August 2026. The company responded swiftly by activating its cybersecurity protocols and engaging external experts to investigate the incident. Despite the breach, NovoCure does not anticipate a material financial impact at this time.
- NVCR’s Price-to-Sales (P/S) ratio of 2.87 is significantly below its historical median of 12.94, indicating that the market is pricing in subdued future growth prospects; earnings-based valuation metrics like P/E are not applicable due to persistent losses.
- The company holds a GF Score™ of 70/100, reflecting a balanced mix of strengths and weaknesses across financial health, profitability, growth, valuation, and momentum.
- Insider activity over the past 12 months shows net selling, with $3.3 million in shares sold versus $1.0 million purchased, while four prominent gurus hold NVCR shares—two have increased and two have trimmed their positions recently.
What’s Behind the News?
In mid-August 2026, NovoCure identified unauthorized access to its information systems via one of its subsidiaries. The breach exposed internal patient identification numbers for over 1,400 U.S. patients, which do not include names or other direct identifiers. More detailed personal data from fewer than 50 patients in the western U.S. was also accessed, along with contact information for healthcare providers and employee details such as job titles and phone numbers. Crucially, no medical treatment devices or operational systems were compromised, and the company’s core operations remain unaffected.
Founded as an oncology-focused medical device company, NovoCure Ltd specializes in Tumor Treating Fields (TTFields) technology, which delivers low-intensity electric fields to combat solid tumors. Its flagship products include Optune Gio and Optune Lua, targeting cancers such as glioblastoma and non-small cell lung cancer. With a market capitalization of $2.06 billion, NovoCure operates primarily in the healthcare sector, generating most of its revenue from the U.S. market, supplemented by sales in Germany, Japan, and other countries.
Is NVCR Overvalued on a Price-to-Sales Basis?
Analyzing NovoCure’s valuation through the Price-to-Sales lens reveals a striking disparity. NVCR’s current P/S ratio stands at 2.87, which is substantially lower than its historical median of approximately 12.9x. This suggests that investors are pricing in a significant slowdown or uncertainty in future revenue growth. The company’s trailing twelve months (TTM) sales of $699 million and a modest 3-year revenue growth rate of 4.6% reinforce this cautious outlook. Given NovoCure’s ongoing unprofitability—with a negative operating margin of -22.08% and net margin of -21.25%—earnings-based valuation metrics such as the P/E ratio are not meaningful and thus are not used for valuation comparisons.
GuruFocus’ proprietary GF Value™ metric estimates NovoCure’s intrinsic value at $18.27 per share, which is about 3.4% above the current market price of $17.65. While this suggests a slight undervaluation, it is important to interpret GF Value™ cautiously for loss-making companies like NVCR, as it relies heavily on historical multiples that may not fully capture the company’s future prospects or risks. For more on GF Value™, see here.
What Does NVCR’s GF Score™ Tell Us?
The GF Score™ is a composite measure designed to provide a snapshot of a company’s overall financial health, growth potential, profitability, valuation, and momentum. NovoCure’s GF Score™ of 70 out of 100 indicates a moderately strong profile, with particular strengths in valuation and momentum but notable weaknesses in profitability.
| Metric | Rating (out of 10) |
|---|---|
| GF Score™ | 70 |
| Financial Strength | 5 |
| Profitability | 2 |
| Growth | 6 |
| Valuation | 9 |
| Momentum | 10 |
While NovoCure exhibits solid momentum and attractive valuation metrics relative to its history, its profitability remains a challenge, reflected in a low profitability rank of 2/10. Financial strength is moderate, with an Altman Z-Score of 1.16 signaling distress risk, and a debt-to-equity ratio of 0.69 indicating manageable leverage. Growth metrics are middling, consistent with the company’s modest revenue expansion. For a detailed view, visit the NVCR stock page.
What Are Gurus and Insiders Doing with NVCR?
GuruFocus tracks that four prominent investment gurus currently hold NovoCure shares. Among them, two have increased their positions while two have trimmed theirs in recent quarters, reflecting a balanced but active interest from institutional smart money. This guru ownership data is a key differentiator of GuruFocus, offering insights unavailable from other platforms like Simply Wall St or Morningstar.
Insider activity over the past 12 months shows net selling, with insiders offloading $3.3 million worth of shares against $1.0 million in purchases. This net selling trend may signal caution from those with the most intimate knowledge of the company’s prospects, though it is not uncommon in biotech and medical device firms facing profitability challenges.
What This Means for Investors
For investors evaluating NovoCure, the key takeaway is that the market is pricing NVCR with tempered expectations for future growth, as evidenced by the low Price-to-Sales ratio relative to its historical median. The company’s persistent losses and negative cash flow render earnings-based valuation metrics ineffective, making revenue-based and proprietary measures like GF Value™ more relevant, albeit with caution. Guru and insider ownership patterns add nuance, showing mixed sentiment but continued institutional interest. The recent cybersecurity breach, while serious, does not currently threaten operations or financial performance but warrants monitoring.
Overall, NovoCure’s valuation appears fairly valued to slightly undervalued on a revenue basis, but investors should weigh this against profitability headwinds and operational risks. For ongoing updates and comprehensive data, visit the NVCR stock page or explore opportunities through the GuruFocus Stock Screener.
Frequently Asked Questions
What is NVCR’s GF Score™?
NVCR’s GF Score™ is 70 out of 100, indicating a moderate overall financial profile with strong valuation and momentum but weak profitability. The score aggregates multiple financial dimensions to provide a holistic view.
Is NVCR overvalued or undervalued?
Based on Price-to-Sales, NVCR appears undervalued relative to its historical median, with a current P/S of 2.87 versus a median of 12.94. Earnings-based valuation like P/E is not meaningful due to ongoing losses.
What is NVCR’s P/E ratio compared to historical?
NVCR does not have a meaningful P/E ratio as it is currently unprofitable. Instead, financial strength indicators such as an Altman Z-Score of 1.16 suggest some distress risk, underscoring the importance of alternative valuation metrics.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
